These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 32588428)

  • 21. Treatment of myelodysplastic syndrome in the era of next-generation sequencing.
    Tobiasson M; Kittang AO
    J Intern Med; 2019 Jul; 286(1):41-62. PubMed ID: 30869816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
    Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
    Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Progress of cytogenetic detection in myelodysplastic syndromes].
    Zhou QB; Hu XM; Liu -; Ma R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1536-40. PubMed ID: 22169320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Utility of Targeted Next-Generation Sequencing Assay to Detect Copy Number Variants Associated with Myelodysplastic Syndrome in Myeloid Malignancies.
    Jiang L; Pallavajjala A; Huang J; Haley L; Morsberger L; Stinnett V; Hardy M; Park R; Ament C; Finch A; Shane A; Parish R; Nozari A; Long P; Adams E; Smith K; Parimi V; Dougaparsad S; Long L; Gocke CD; Zou YS
    J Mol Diagn; 2021 Apr; 23(4):467-483. PubMed ID: 33577993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cytogenetics of myelodysplastic syndromes and its impact as prognostic factor].
    Borjas-Gutiérrez C; Domínguez-Cruz MD; González-García JR
    Rev Med Inst Mex Seguro Soc; 2017; 55(4):481-489. PubMed ID: 28591503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The value of next-generation sequencing in routine diagnostics and management of patients with cytopenia.
    Breinholt MF; Nielsen K; Schejbel L; Fassi DE; Schöllkopf C; Novotny GW; Mortensen BK; Ahmad A; Høgdall E; Nørgaard P
    Int J Lab Hematol; 2022 Jun; 44(3):531-537. PubMed ID: 35142436
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Updates in cytogenetics and molecular markers in MDS.
    Tiu RV; Visconte V; Traina F; Schwandt A; Maciejewski JP
    Curr Hematol Malig Rep; 2011 Jun; 6(2):126-35. PubMed ID: 21340513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [How Myelodysplastic Syndrome is Diagnosed].
    Silzle T
    Ther Umsch; 2022; 79(2):77-85. PubMed ID: 35291852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies.
    Bhai P; Hsia CC; Schenkel LC; Hedley BD; Levy MA; Kerkhof J; Santos S; Stuart A; Lin H; Broadbent R; Nan S; Yang P; Xenocostas A; Chin-Yee I; Sadikovic B
    Mol Diagn Ther; 2022 May; 26(3):333-343. PubMed ID: 35381971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.
    Bidet A; Dulucq S; Smol T; Marceau-Renaut A; Morisset S; Coiteux V; Noël-Walter MP; Nicolini FE; Tigaud I; Luquet I; Struski S; Gaillard B; Penther D; Tondeur S; Nadal N; Hermet E; Véronèse L; Réa D; Gervais C; Theisen O; Terré C; Cony-Makhoul P; Lefebvre C; Gaillard JB; Radford I; Vervaeke AL; Barin C; Chapiro E; Nguyen-Khac F; Etienne G; Preudhomme C; Mahon FX; Roche-Lestienne C;
    Haematologica; 2019 Jun; 104(6):1150-1155. PubMed ID: 30573507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational profiling in patients with MDS: ready for every-day use in the clinic?
    Bacher U; Kohlmann A; Haferlach T
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):32-42. PubMed ID: 25659728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiparameter flow cytometry provides independent prognostic information in patients with suspected myelodysplastic syndromes: A study on 804 patients.
    Kern W; Bacher U; Haferlach C; Alpermann T; Schnittger S; Haferlach T
    Cytometry B Clin Cytom; 2015; 88(3):154-64. PubMed ID: 25581461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
    Polprasert C; Niparuck P; Rattanathammethee T; Chuncharunee S; Kobbuaklee S; Songserm K; Suksusut A; Trithiphen S; Lanamtieng T; Kongkiatkamon S; Chanswangphuwana C; Lawasut P; Bunworasate U; Rojnuckarin P
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e293-e299. PubMed ID: 34840089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms.
    Liquori A; Lesende I; Palomo L; Avetisyan G; Ibáñez M; González-Romero E; Boluda-Navarro M; Morote-Faubel M; Garcia-Ruiz C; Martinez-Valiente C; Santiago-Balsera M; Gomez-Seguí I; Sanjuan-Pla A; Sanz MA; Sanz G; Solé F; Such E; Cervera J
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33919541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Standardizing the initial evaluation for myelodysplastic syndromes.
    Marshall D; Roboz GJ
    Curr Hematol Malig Rep; 2013 Dec; 8(4):361-9. PubMed ID: 24178514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey.
    Pine AB; Chokr N; Stahl M; Steensma DP; Sekeres MA; Litzow MR; Luger SM; Stone RM; Greenberg PL; Bejar R; Bewersdorf JP; Gore SD; Zeidan AM
    Leuk Lymphoma; 2020 Jun; 61(6):1455-1464. PubMed ID: 32026740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of cytomorphology, cytogenetics, molecular genetics, and immunophenotyping in a comprehensive diagnostic workup of myelodysplastic syndromes.
    Bacher U; Haferlach T; Kern W; Weiss T; Schnittger S; Haferlach C
    Cancer; 2009 Oct; 115(19):4524-32. PubMed ID: 19569249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-nucleotide polymorphism array (SNP-A) improves the identification of chromosomal abnormalities by metaphase cytogenetics in myelodysplastic syndrome.
    da Silva FB; Machado-Neto JA; Bertini VHLL; Velloso EDRP; Ratis CA; Calado RT; Simões BP; Rego EM; Traina F
    J Clin Pathol; 2017 May; 70(5):435-442. PubMed ID: 27836923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes.
    Solé F; Luño E; Sanzo C; Espinet B; Sanz GF; Cervera J; Calasanz MJ; Cigudosa JC; Millà F; Ribera JM; Bureo E; Marquez ML; Arranz E; Florensa L
    Haematologica; 2005 Sep; 90(9):1168-78. PubMed ID: 16154839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Brief Overview of the Molecular Landscape of Myelodysplastic Neoplasms.
    Abdulbaki R; Pullarkat ST
    Curr Oncol; 2024 Apr; 31(5):2353-2363. PubMed ID: 38785456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.